ASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

English - September 16, 2012 23:11 - 4 minutes - 4.5 MB - ★★★★★ - 1 rating
Science Health & Fitness Medicine grace cancergrace gracecast lung cancer nsclc chemotherapy chemo radiation non Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)

Next Episode: ASCO 2012 LC Highlights: Dr. Joel Neal on Molecular Targets in Squamous NSCLC (audio)

Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.